EFFICACY, SAFETY, AND PATIENT OUTCOMES OF EMERGENCY TREATMENT WITH IV INSULIN-DEXTROSE IN PATIENTS WITH HYPERKALEMIA

H ASHRAF; F KHURRAM; F ASHRAF

doi:10.54112/bcsrj.v2024i1.991

Authors

H ASHRAF Department of Emergency Medicine, Shifa International Hospital Islamabad, Pakistan
F KHURRAM Federal Medical College Islamabad, Pakistan
F ASHRAF Department of Medicine, Holy Family Hospital Rawalpindi, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.991

Keywords:

Emergency Treatment, Hyperkalemia, Hypoglycemia, Insulin, Retrospective Studies, Safety

Abstract

Hyperkalemia is a potentially life-threatening condition often encountered in emergency settings. Insulin-dextrose infusion is a common treatment to rapidly lower serum potassium levels, but this approach carries risks, particularly related to glucose imbalances. Objective: To evaluate the efficacy, safety, and clinical outcomes of insulin-dextrose infusion in the emergency treatment of patients with hyperkalemia. Methods: This retrospective study was conducted in the Emergency Department of Shifa International Hospital Islamabad from June 2023 to June 2024. The study included 400 patients with recorded potassium levels. Patients were categorized into non-hyperkalemic (K+ <5.5 mmol/L) and hyperkalemic (K+ ≥ 5.5 mmol/L) groups. Hyperkalemic patients received an insulin-dextrose infusion consisting of an average of 10 units of Actrapid insulin and 50 milliliters of 50% dextrose. Clinical outcomes, including efficacy and safety, were compared between treated hyperkalemic patients and those with moderate-severe hyperkalemia who did not receive the treatment. Statistical analysis was performed using odds ratios (OR) and 95% confidence intervals (CI) to assess the association between treatment variables and outcomes. Results: Glucose imbalances were observed in 60% of patients treated with insulin, with 50% developing hyperglycemia and 20% experiencing hypoglycemia, including 5% with severe hypoglycemia six hours post-treatment. Factors significantly associated with hypoglycemia included multiple insulin doses (OR: 2.9, 95% CI: 2.0-3.9), chronic kidney disease (CKD) (OR: 1.3, 95% CI: 1.0-2.1), and baseline glucose levels below seven mmol/L (OR: 3.0, 95% CI: 2.2-4.2). Hypoglycemic patients had a higher risk of mortality (OR: 1.49, 95% CI: 1.11-2.11). ICU admission occurred in three patients treated with insulin, with a higher risk associated with multiple doses (OR: 1.8, 95% CI: 1.4-2.9) and insulin doses greater than ten units (OR: 5.3, 95% CI: 2.9-10). Conclusion: The use of insulin-dextrose infusion in the emergency management of hyperkalemia is associated with a significant risk of hypoglycemia, ICU admission, and prolonged hospital stay. These findings suggest the need for improved treatment protocols to enhance patient safety in emergency settings.

Downloads

Download data is not yet available.

References

Hunter RW, Bailey MA. Hyperkalemia: pathophysiology, risk factors and consequences. Nephrology Dialysis Transplantation. 2019;34(Supplement_3):iii2-iii11.

Liu M, Rafique Z. Acute management of hyperkalemia. Current heart failure reports. 2019;16:67-74.

Esposito P, Conti NE, Falqui V, Cipriani L, Picciotto D, Costigliolo F, et al. New treatment options for hyperkalemia in patients with chronic kidney disease. Journal of Clinical Medicine. 2020;9(8):2337.

Moussavi K, Fitter S, Gabrielson SW, Koyfman A, Long B. Management of hyperkalemia with insulin and glucose: pearls for the emergency clinician. The Journal of Emergency Medicine. 2019;57(1):36-42.

Moussavi K, Nguyen LT, Hua H, Fitter S. Comparison of IV insulin dosing strategies for hyperkalemia in the emergency department. Critical Care Explorations. 2020;2(4):e0092.

Thani SA, Al Farsi M, Al Omrani S. Life-threatening hyperkalemia treated with prolonged continuous insulin infusion. International Journal of Pediatrics and Adolescent Medicine. 2019;6(3):118-20.

Alam S, Ishaqui AA, Khan MA, Iqbal A, Jawed SH, Khalid F, et al. Evaluation of single-dose sodium polystyrene sulfonate for management of hyperkalemia and its effect on other serum electrolytes. Pakistan Armed Forces Medical Journal. 2019;69(1):37-42.

Garcia J, Pintens M, Morris A, Takamoto P, Baumgartner L, Tasaka CL. Reduced versus conventional dose insulin for hyperkalemia treatment. Journal of Pharmacy Practice. 2020;33(3):262-6.

Keeney KP, Calhoun C, Jennings L, Weeda ER, Weant KA. Assessment of intravenous insulin dosing strategies for the treatment of acute hyperkalemia in the emergency department. The American Journal of Emergency Medicine. 2020;38(6):1082-5.

Lim SH, Wahab SNB, Ang SY, Teh MM, Aloweni F. Evaluation of Care Outcomes of Patients Receiving Hyperkalemia Treatment With Insulin in Acute Care Tertiary Hospital Emergency Department. Journal of Emergency Nursing. 2023;49(1):99-108.

Wetmore JB, Yan H, Horne L, Peng Y, Gilbertson DT. Risk of hyperkalemia from renin–angiotensin–aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population. Nephrology Dialysis Transplantation. 2021;36(5):826-39.

Moussavi K, Garcia J, Tellez‐Corrales E, Fitter S. Reduced alternative insulin dosing in hyperkalemia: a meta‐analysis of effects on hypoglycemia and potassium reduction. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2021;41(7):598-607.

Boughton CK, Dixon D, Goble E, Burridge A, Cox A, Noble‐Bell G, et al. Preventing hypoglycemia following treatment of hyperkalemia in hospitalized patients. Journal of Hospital Medicine. 2019;14(5):284-7.

Crnobrnja L, Metlapalli M, Jiang C, Govinna M, Lim AK. The association of insulin-dextrose treatment with hypoglycemia in patients with hyperkalemia. Scientific Reports. 2020;10(1):22044.

Abou Sherif S, Katsaiti I, Jebb H, Banh S, Bedi R, Levy J, et al. Reducing the harm associated in treating hyperkalaemia with insulin and dextrose. Clinical Medicine. 2024:100222.